Labmicta

Name

Labmicta

Legal name

Stichting Labmicta

Website

https://labmicta.nl

Company type

Private

Founded year

1949

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Medical Microbiology Laboratory Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Analytical Laboratory Instrument Manufacturing (334516)

SIC

Services-Medical Laboratories (8071), Services-Testing Laboratories (8734), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Microbiology & Infectious Disease Testing Laboratories (HLAFAMAD)

akta.pro secondary industries

Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels) (HLAAALAC), Disease-Specific Reference Laboratory Networks (e.g., TB, HIV, Influenza) (HLAJAIAD), Biothreat/Biocontainment & Select Agent Public Health Laboratories (HLAJAIAL)

Keywords

• Medical microbiology diagnostics
• Infectious disease testing
• Clinical laboratory services
• Antibiotic stewardship consulting
• Infection prevention services

Headquarters

HQ city

Hengelo

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Medical Diagnostics Services: Labmicta performs diagnostic testing on patient material (body fluids, tissue) for healthcare providers (hospitals, GPs, care institutions, midwives). Revenue is generated through diagnostic testing fees billed to healthcare insurers, healthcare institutions, or patients directly, based on regulated healthcare pricing in the Netherlands. Services include routine microbiology, specialized testing, molecular diagnostics, NGS, and BSL-3 tuberculosis diagnostics.
2. Publicly Disclosed Tariffs for First-Line Care: Labmicta publishes fee schedules (tarieven 1e lijn) for first-line care diagnostics on its website, indicating transparent, published pricing for GP-ordered diagnostics. This suggests a mix of regulated fee-for-service billing for primary care providers.
3. Consultation and Advisory Services: Physicians-microbiologists provide clinical consultations to healthcare providers based on diagnostic results, advising on optimal treatment. This forms part of the integrated diagnostic service offering, billed within the diagnostic pathway.
4. Infection Prevention Support Services: Infection prevention specialists support GP practices (primary care) and nursing/care homes (VVT) with practical support and training. This is part of Labmicta's integrated 'complete palette of infection care' and is funded as part of regional healthcare quality improvement initiatives.
5. Point of Care Testing (POCT) Equipment & Services: Labmicta installs POCT ('mini-labs') at healthcare locations, trains staff, and provides ongoing support. This generates revenue through device placement, consumables, and service contracts with healthcare providers.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Core offering

Labmicta is an independent medical microbiology laboratory that delivers comprehensive infectious disease diagnostics and clinical consultation to healthcare providers. Services span routine microbiology (bacteriology, virology, serology, mycology, parasitology), Next Generation Sequencing (NGS) for pathogen detection and surveillance, BSL-3 tuberculosis diagnostics, high-volume testing, Point of Care Testing, infection prevention consulting, and antibiotic stewardship, complemented by embedded physicians-microbiologists in partner hospitals.

Product overview

Labmicta operates as an independent foundation medical microbiology laboratory offering a comprehensive infectious disease care portfolio including prevention, outbreak containment, antibiotic stewardship, and broad diagnostics with physician consultation. The laboratory holds a unique 'double status' position in Dutch microbiology, providing both high-volume low-complexity testing (including a dedicated high-volume COVID-19 laboratory processing over 12,000 samples daily) and highly specialized diagnostics. Core offerings include advanced Next Generation Sequencing (NGS) technology for genomic surveillance and pathogen detection, BSL-3 laboratory services for tuberculosis diagnostics, and Point of Care Testing (POCT) deployed at healthcare facilities. Digital infrastructure includes the IDON platform for integrated East Netherlands diagnostics and the Regionaal Diagnostisch Portaal for unified ordering and results viewing across multiple laboratory partners. Supporting services encompass infection prevention consultation, antibiotic policy support, and clinical staff embedded in partner hospitals.

Differentiator

Problem solved

Functional benefit

Products and services

• Medical Microbiology Diagnostics

Quantifiable outcome

• Processes up to 12,000 COVID-19 specimens per day in the high-volume laboratory
• +3 more outcomes

Named customers8 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability5 records

Feature5 records

Partnerships

17 partnerships are on record, tiered core and minor.

• Universiteit Twente (UT)coreStrategic or Co-development PartnerLabmicta and the University of Twente have a multi-year collaboration (signed April 2025) to optimize laboratory processes using AI and robotics. A PhD student from UT conducts research on AI and robotization in Labmicta's laboratory, guided by experts from both organizations. The collaboration aims for faster, more efficient, and more sustainable laboratory diagnostics for better patient care. Supported by health insurer Menzis.
• UMCG (Universitair Medisch Centrum Groningen)coreStrategic or Co-development PartnerLabmicta collaborates with UMCG on two recognized academic training positions for physicians-microbiologists and medical molecular microbiologists. AIOS (doctors in training) can complete part of their specialization at Labmicta. This connects education, science, and practice.
• ZGT (Ziekenhuisgroep Twente)coreTechnology or IntegrationLabmicta embeds physicians-microbiologists at ZGT hospitals in Almelo and Hengelo. Services include full microbiology diagnostics, antibiotic stewardship consultation, and clinical advice as co-treating physician.
• MST (Medisch Spectrum Twente)coreTechnology or IntegrationLabmicta embeds physicians-microbiologists at MST in Enschede. Close collaboration includes joint dashboards monitoring diagnostic ordering data to ensure high-quality, cost-effective care. MST is the primary partner for data-driven diagnostic improvement projects.
• SKB (Streekziekenhuis Koninginnedal Winterswijk)coreTechnology or IntegrationLabmicta embeds physicians-microbiologists at SKB in Winterswijk for diagnostic services and clinical consultation.
• Saxenburgh (Hardenberg)coreTechnology or IntegrationLabmicta embeds physicians-microbiologists at Saxenburgh hospital in Hardenberg for microbiology diagnostics and consultation.
• GGD TwentecoreTechnology or IntegrationA physician-microbiologist from Labmicta is permanently detached to GGD Twente to support public health infectious disease management, notification, and outbreak coordination.
• LabPON (pathologie)coreStrategic or Co-development PartnerLabmicta and LabPON share a Bedrijfsbureau (shared business office) and jointly develop the Regional Diagnostic Portal (Regionaal Diagnostisch Portaal) for integrated medical diagnostics across Twente.
• Unilabs/MedloncoreStrategic or Co-development PartnerLabmicta, LabPON, and Unilabs/Medlon are the three diagnostic organizations collaborating on the Regional Diagnostic Portal under the 'Versneld verbinden' program for digital healthcare transformation in Twente.
• RIVMcoreTechnology or IntegrationLabmicta conducts germ surveillance for RIVM, sequencing 50 random COVID-19 specimens per week to monitor variants and virus evolution. Also developed test protocols for tuberculosis and COVID-19 NGS diagnostics with RIVM for the international 'Nooit meer een pandemie' project.
• Coöperatie MenziscoreStrategic or Co-development PartnerMenzis, the largest health insurer in Twente, supports Labmicta's collaboration with the University of Twente (AI/robotics project) and the regional Versneld verbinden digital transformation initiative. Menzis was involved from the start of the IDON cooperative formation in 2021.
• SHT-THOON (regional GP organization)coreStrategic or Co-development PartnerLabmicta and SHT-THOON formed a unique collaboration to create 'De Symfonie' — a primary care health center in Oldenzaal in a former school building. Labmicta invested as part of its ANBI mission to support regional healthcare. This collaboration exemplifies Labmicta's entrepreneurial, needs-driven approach.
• IDON (Integrale Diagnostiek Oost-Nederland)coreStrategic or Co-development PartnerIDON is a cooperative founded in October 2021 by Labmicta, LabPON, Medlon BV, and MRON, with Menzis as founding partner. IDON's first project is a single digital regional platform for all medical diagnostics — ordering and results for blood, urine, feces, tissue, and radiological examinations — for GPs in the region.
• KNCV TuberculosefondsminorStrategic or Co-development PartnerLabmicta participates in the KNCV Tuberculosefonds' international 'Nooit meer een pandemie' (No More Pandemic) project funded by €11 million from the Nationale Postcode Loterij's Droomfonds. Labmicta trained laboratory staff and PhD students from Kyrgyzstan, Tanzania, and Vietnam in Next Generation Sequencing (NGS) techniques for COVID-19 and tuberculosis diagnostics using Oxford Nanopore's MinION device.
• Roessingh (rehabilitation center)minorOthersRegional healthcare partner of Labmicta, shown in the partner logos section on the homepage.
• GGD Regio TwenteminorOthersRegional public health partner collaborating on infection prevention and data exchange programs.
• Versneld verbinden consortium (25+ organizations)coreStrategic or Co-development PartnerLabmicta leads (kartrekker) the Versneld verbinden regional digital transformation program involving 25+ Twentse healthcare organizations, funded through the IZA (Integraal Zorgakkoord). Key usecases include the Regional Diagnostic Portal and broader data exchange infrastructure for future-proof regional healthcare.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Izore: Izore is the regional medical microbiology laboratory in Friesland, Netherlands. Directly comparable as another Dutch regional microbiology lab foundation providing infectious disease diagnostics, outbreak support, and public health collaboration to hospitals and GGDs in its region.
• Stichting PAMM: Stichting PAMM is a Dutch regional medical microbiology laboratory serving the Eindhoven region. Directly comparable as another non-hospital medical microbiology foundation providing infectious disease diagnostics, antibiotic stewardship consultation, and BSL-level microbiology services to regional hospitals and primary care.
• Unilabs / Medlon: Unilabs (which includes Medlon) is a direct peer and explicit partner of Labmicta in the IDON cooperative and Regional Diagnostic Portal. Both organizations provide medical diagnostics services to Dutch healthcare providers, with Unilabs/Medlon serving as the regional clinical chemistry counterpart to Labmicta's microbiology focus.
• LabPON: LabPON is a regional pathology laboratory in East Netherlands and a direct partner of Labmicta — they share a Bedrijfsbureau (business office) and jointly developed the Regional Diagnostic Portal. Operates in the same regional market with complementary specialty (pathology vs. microbiology).
• Star-SHL: Star-SHL is a Dutch regional medical diagnostics foundation providing clinical chemistry, microbiology, and pathology services to primary care and hospitals. Comparable as another non-profit regional diagnostics foundation operating under similar Dutch healthcare regulatory dynamics.

Broad incumbents

• Cerba Healthcare: Cerba Healthcare is a European medical diagnostics group providing routine and specialty laboratory services across multiple geographies. Comparable as a broad incumbent in clinical diagnostics with microbiology and infectious disease testing capabilities, operating at significantly larger scale than Labmicta.
• Synlab: Synlab is one of Europe's largest medical diagnostics services providers, operating across multiple countries including Germany and other European markets. Comparable as a large-scale incumbent in medical laboratory services with overlapping capabilities in clinical chemistry, microbiology, and specialty diagnostics — though not specifically focused on the Dutch regional microbiology niche.
• Eurofins Scientific: Eurofins is a global leader in bioanalytical testing including clinical diagnostics and microbiology. Comparable as a broad incumbent in testing laboratory services with overlap in infectious disease diagnostics, genomic sequencing, and clinical microbiology — though operates at vastly greater scale and scope than Labmicta.

Others

• RIVM (Rijksinstituut voor Volksgezondheid en Milieu): RIVM is the Dutch National Institute for Public Health and the Environment, and a core partner of Labmicta for national germ surveillance (COVID-19 variant sequencing). Included as a peer for the public-health reference laboratory and surveillance function Labmicta performs under RIVM contract — not a direct competitor, but a defining ecosystem relationship for reference-level diagnostics.

Regional players

• Saltro: Saltro is a Dutch primary care diagnostics provider (part of the U-Diagnostics group) serving general practitioners with laboratory testing. Comparable in target customer base (Dutch primary care providers) and regional diagnostics delivery model, but focuses on clinical chemistry and primary care diagnostics rather than medical microbiology specialty.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/labmicta
• LinkedInlinkedin.com/company/labmicta
• Instagraminstagram.com/labmicta
• TikToktiktok.com/@labmicta

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles20 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Labmicta